Skip to main content

Table 1 Baseline characteristic and PRINTO core set measures at onset of the study population

From: The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

 

Group 1

(CR yes-TF no-PDN off)

N = 30

Group 2

(CR no-TF no/PDN on or off)N = 43

Group 3

(CR no-TF yes/PDN on or off) N = 66

P *

Age at onset (years)

9.5 (6.2–12.3)

6.5 (3.3–9.8)

6.9 (4.2–10)

0.016

Disease duration (mo)

2.6 (1.3–4.7)

2.6 (1.3–6.4)

3.0 (1.5–4.8)

0.94

MD-global (0–10 ↑)

7.0 (6.0–8.0)

6.0 (5.0–7.0)

7.0 (5.0–8.0)

0.17

Parent global (0–10 ↑)

6.0 (5.0–8.0)

5.0 (3.5–7.0)

5.4 (5.0–7.0)

0.40

CHAQ (0–3 ↑)

1.8 (1.1–2.6)

1.8 (1.4–2.6)

1.9 (1.3–2.5)

0.94

DAS (0–20 ↑)

13.0 (11.0–15.0)

13.0 (11.0–15.0)

13.0 (11.0–15.0)

0.80

CMAS (0–52 ↓)

16.5 (13.0–33.0)

21.0 (14.0–35.0)

20.7 (11.0–32.0)

0.96

MMT (0–80 ↓)

40.0 (30.0–60.0)

47.0 (35.0–58.0)

48.0 (34.0–56.0)

0.84

CHQ PhS (40–60 ↓)

19.8 (9.4–33.4)

12.7 (5.2–23.5)

14.9 (8.1–22.4)

0.16

  1. Data are medians (1st 3rdquartiles). *P: P value refers to the non-parametric Analysis of Variance (Kruskal-Wallis test); MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score; CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing; CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire); ↑ indicates that higher values correspond to a worse outcome; ↓ indicates that lower values correspond to a worse outcome